Dr. Lamy has been involved in clinical research since the beginning of his career and has collaborated with many research groups and pharmaceutical and devices companies around the world. His interests are centred on large, randomized controlled trials (RCT) in cardiac surgery and health economics.
His most significant contribution in cardiac surgery is the CORONARY trial for which he received a large grant from the Canadian Institute of Health Research in 2007. CORONARY is a large multi centred randomized trial of off-pump CABG surgery versus on-pump CABG surgery. CORONARY has recruited and randomized 4,752 patients from 79 centres in 19 countries. The results were presented at the Late Breaking Clinical Trials at the American College of Cardiology meeting in 2012 and 2013 and were published in the New England Journal of Medicine in 2012 and 2013. The trial recently finished with a follow-up of five years. These final results were published in the New England Journal of Medicine October 2016.
Over the years, Dr. Lamy has also accumulated a large database of cardiovascular costs in about 40 countries and produced economic analyses of major trials such as HOPE, CURE, ACTIVE-A, ORIGIN, ONTARGET, TIMACS, and CORONARY. He is also contributing with on-going trials such as HOPE-3, COMPLETE, and HIP ATTACK.
Dr. Lamy is currently involved with the VISION-Cardiac surgery trial, a prospective analysis of 15,000 patients around the world to determine the cut-off value and prognostic factor of the new generation of troponin essays after cardiac surgery